JPWO2021108605A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021108605A5 JPWO2021108605A5 JP2022530262A JP2022530262A JPWO2021108605A5 JP WO2021108605 A5 JPWO2021108605 A5 JP WO2021108605A5 JP 2022530262 A JP2022530262 A JP 2022530262A JP 2022530262 A JP2022530262 A JP 2022530262A JP WO2021108605 A5 JPWO2021108605 A5 JP WO2021108605A5
- Authority
- JP
- Japan
- Prior art keywords
- forskolin
- insulin
- combination
- active ingredients
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 60
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 60
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 42
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 30
- 102000004877 Insulin Human genes 0.000 claims description 30
- 108090001061 Insulin Proteins 0.000 claims description 30
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 30
- 229940125396 insulin Drugs 0.000 claims description 30
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 26
- 229930003268 Vitamin C Natural products 0.000 claims description 26
- 235000019154 vitamin C Nutrition 0.000 claims description 26
- 239000011718 vitamin C Substances 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 23
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 8
- 208000017004 dementia pugilistica Diseases 0.000 claims description 8
- 210000004498 neuroglial cell Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 230000004766 neurogenesis Effects 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 201000002773 amyotrophic lateral sclerosis type 13 Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 208000034189 Sclerosis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962939964P | 2019-11-25 | 2019-11-25 | |
| US62/939,964 | 2019-11-25 | ||
| PCT/US2020/062295 WO2021108605A1 (en) | 2019-11-25 | 2020-11-25 | Composition and method for converting human glial cells into neurons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023502785A JP2023502785A (ja) | 2023-01-25 |
| JPWO2021108605A5 true JPWO2021108605A5 (de) | 2023-12-01 |
Family
ID=76128938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530262A Pending JP2023502785A (ja) | 2019-11-25 | 2020-11-25 | ヒトグリア細胞をニューロンに変換するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220395483A1 (de) |
| EP (1) | EP4065091A4 (de) |
| JP (1) | JP2023502785A (de) |
| CN (1) | CN115135312A (de) |
| AU (1) | AU2020392124A1 (de) |
| CA (1) | CA3162890A1 (de) |
| WO (1) | WO2021108605A1 (de) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001088104A2 (en) * | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
| US7736892B2 (en) * | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
| US9574173B2 (en) * | 2010-11-15 | 2017-02-21 | Accelerated Biosciences Corp. | Generation of neural stem cells from human trophoblast stem cells |
| WO2016086092A1 (en) * | 2014-11-25 | 2016-06-02 | The Penn State Research Foundation | Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair |
| GB201421092D0 (en) * | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| US9885015B2 (en) * | 2015-12-04 | 2018-02-06 | The Penn State Research Foundation | Chemical reprogramming of human glial cells into neurons with small molecule cocktail |
| CN111500538A (zh) * | 2017-03-01 | 2020-08-07 | 中国科学院动物研究所 | 一种将非神经元细胞转化为神经元细胞的方法 |
-
2020
- 2020-11-25 EP EP20893871.2A patent/EP4065091A4/de active Pending
- 2020-11-25 JP JP2022530262A patent/JP2023502785A/ja active Pending
- 2020-11-25 AU AU2020392124A patent/AU2020392124A1/en active Pending
- 2020-11-25 CN CN202080081782.XA patent/CN115135312A/zh active Pending
- 2020-11-25 US US17/779,418 patent/US20220395483A1/en active Pending
- 2020-11-25 WO PCT/US2020/062295 patent/WO2021108605A1/en unknown
- 2020-11-25 CA CA3162890A patent/CA3162890A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schmidt et al. | Use of pramipexole in REM sleep behavior disorder: results from a case series | |
| DE60120937T2 (de) | Mikroeingekapselte duftstoffe und verfahren zur beschichtung von mikrokapseln | |
| EP1648433B1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| ATE444750T1 (de) | Neurorestauration mit r(+) pramipexol | |
| JP2003335704A (ja) | 制汗剤と抗菌剤の複合組成物 | |
| Geckil et al. | The relationship between anxiety, depression, daytime sleepiness in the REM-related mild OSAS and the NREM-related mild OSAS | |
| Kurlan | Treatment of tics | |
| JPWO2021108605A5 (de) | ||
| JPH09500121A (ja) | 痴呆症の治療のためのナブメトンまたは６−メトキシナフチル酢酸の使用 | |
| JP2021503483A5 (de) | ||
| Marous et al. | Complementary and alternative methods for treatment of acne vulgaris: a systematic review | |
| Dolberg et al. | Differential effects of topiramate in patients with traumatic brain injury and obesity—a case series | |
| Wang | Why placebos work wonders | |
| Ostrom et al. | Randomized trial to assess the efficacy and safety of beclomethasone dipropionate breath-actuated inhaler in patients with asthma | |
| CN1290166A (zh) | 运动障碍的治疗 | |
| Ordman | Nutritional Steps to Maintain Health and Reduce Cancer Risk | |
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| Suvar | Antidepressants | |
| Mechcatie | Pregabalin is first drug approved for fibromyalgia | |
| Todd et al. | The Long-Lasting Effects of Cannabis Use on Movement and Brain Regions that Control Movement | |
| Riboldi | Posthypoxic Myoclonus and Its Management | |
| CN106309417A (zh) | 用于治疗帕金森相关疾病药物组合物 | |
| Dowlatshahi et al. | An analysis of major depressive disorder and the effectivity of effexor XR®(Venlafaxine Hydrochloride) in its treatment | |
| Skljarevski et al. | Efficacy and safety of duloxetine 60 mg once-daily in patients with chronic low back pain | |
| Alqudah et al. | Effects of Coriandrum sativum seeds on memory, anxiety, depression, and sleep quality in students: a randomized controlled study |